Corcept Therapeutics (NASDAQ:CORT) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, February 22nd. Analysts expect Corcept Therapeutics to post earnings of $0.18 per share for the quarter.
Corcept Therapeutics (NASDAQ CORT) opened at $15.98 on Tuesday. The company has a market capitalization of $1,823.70, a PE ratio of 55.11 and a beta of 1.68. Corcept Therapeutics has a 52 week low of $8.14 and a 52 week high of $25.96.
In other Corcept Therapeutics news, insider Robert S. Fishman sold 8,000 shares of Corcept Therapeutics stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $16.60, for a total value of $132,800.00. Following the completion of the transaction, the insider now directly owns 8,000 shares in the company, valued at $132,800. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold 24,000 shares of company stock valued at $415,920 over the last quarter. Insiders own 19.20% of the company’s stock.
A number of equities analysts recently commented on the company. BidaskClub upgraded Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 23rd. Piper Jaffray Companies set a $30.00 price target on Corcept Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Zacks Investment Research downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Finally, Stifel Nicolaus decreased their price target on Corcept Therapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, February 5th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $21.00.
ILLEGAL ACTIVITY NOTICE: “Corcept Therapeutics (CORT) Scheduled to Post Earnings on Thursday” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/20/corcept-therapeutics-cort-scheduled-to-post-earnings-on-thursday.html.
Corcept Therapeutics Company Profile
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.